Role of 2-deoxy-2-[18F]-fluoro-d-glucose-PET/computed tomography in lymphoma

Sree Harsha Tirumani, Ann S. Lacasce, Heather A. Jacene

Research output: Contribution to journalArticle

Abstract

The role of PET and PET/computed tomography (CT) has evolved significantly in the last few decades. 2-Deoxy-2-[18F]-fluoro-d-glucose (FDG)-PET/CT is now an integral part of the management of patients with lymphoma. FDG-PET/CT at the time of initial staging can help in appropriate staging of the patients. Both interim and end-of-therapy PETs have significant prognostic value in patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma and more accurately assess for the presence of residual malignancy than anatomic imaging. The impact of interim FDG-PET/CT on risk-adapted strategies is an area of active investigation and the results of ongoing clinical trials will be informative.

Original languageEnglish (US)
Pages (from-to)207-225
Number of pages19
JournalPET Clinics
Volume10
Issue number2
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

glucose
Lymphoma
tomography
Tomography
Glucose
Hodgkin Disease
Non-Hodgkin's Lymphoma
therapy
Clinical Trials
Neoplasms
Therapeutics

Keywords

  • Diffuse large B-cell lymphoma
  • FDG-PET/CT
  • Hodgkin lymphoma
  • Interim PET/CT
  • Lymphoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Role of 2-deoxy-2-[18F]-fluoro-d-glucose-PET/computed tomography in lymphoma. / Tirumani, Sree Harsha; Lacasce, Ann S.; Jacene, Heather A.

In: PET Clinics, Vol. 10, No. 2, 01.04.2015, p. 207-225.

Research output: Contribution to journalArticle

Tirumani, Sree Harsha ; Lacasce, Ann S. ; Jacene, Heather A. / Role of 2-deoxy-2-[18F]-fluoro-d-glucose-PET/computed tomography in lymphoma. In: PET Clinics. 2015 ; Vol. 10, No. 2. pp. 207-225.
@article{be07c7d287da4473a40f18721578b338,
title = "Role of 2-deoxy-2-[18F]-fluoro-d-glucose-PET/computed tomography in lymphoma",
abstract = "The role of PET and PET/computed tomography (CT) has evolved significantly in the last few decades. 2-Deoxy-2-[18F]-fluoro-d-glucose (FDG)-PET/CT is now an integral part of the management of patients with lymphoma. FDG-PET/CT at the time of initial staging can help in appropriate staging of the patients. Both interim and end-of-therapy PETs have significant prognostic value in patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma and more accurately assess for the presence of residual malignancy than anatomic imaging. The impact of interim FDG-PET/CT on risk-adapted strategies is an area of active investigation and the results of ongoing clinical trials will be informative.",
keywords = "Diffuse large B-cell lymphoma, FDG-PET/CT, Hodgkin lymphoma, Interim PET/CT, Lymphoma",
author = "Tirumani, {Sree Harsha} and Lacasce, {Ann S.} and Jacene, {Heather A.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.cpet.2014.12.005",
language = "English (US)",
volume = "10",
pages = "207--225",
journal = "PET Clinics",
issn = "1556-8598",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Role of 2-deoxy-2-[18F]-fluoro-d-glucose-PET/computed tomography in lymphoma

AU - Tirumani, Sree Harsha

AU - Lacasce, Ann S.

AU - Jacene, Heather A.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - The role of PET and PET/computed tomography (CT) has evolved significantly in the last few decades. 2-Deoxy-2-[18F]-fluoro-d-glucose (FDG)-PET/CT is now an integral part of the management of patients with lymphoma. FDG-PET/CT at the time of initial staging can help in appropriate staging of the patients. Both interim and end-of-therapy PETs have significant prognostic value in patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma and more accurately assess for the presence of residual malignancy than anatomic imaging. The impact of interim FDG-PET/CT on risk-adapted strategies is an area of active investigation and the results of ongoing clinical trials will be informative.

AB - The role of PET and PET/computed tomography (CT) has evolved significantly in the last few decades. 2-Deoxy-2-[18F]-fluoro-d-glucose (FDG)-PET/CT is now an integral part of the management of patients with lymphoma. FDG-PET/CT at the time of initial staging can help in appropriate staging of the patients. Both interim and end-of-therapy PETs have significant prognostic value in patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma and more accurately assess for the presence of residual malignancy than anatomic imaging. The impact of interim FDG-PET/CT on risk-adapted strategies is an area of active investigation and the results of ongoing clinical trials will be informative.

KW - Diffuse large B-cell lymphoma

KW - FDG-PET/CT

KW - Hodgkin lymphoma

KW - Interim PET/CT

KW - Lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84964296837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964296837&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2014.12.005

DO - 10.1016/j.cpet.2014.12.005

M3 - Article

C2 - 25829087

AN - SCOPUS:84964296837

VL - 10

SP - 207

EP - 225

JO - PET Clinics

JF - PET Clinics

SN - 1556-8598

IS - 2

ER -